Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314187 | 0.83 | MEN1 (0.43) | HSD11B1POLBTSHRALDH1A1MEN1 | |
| SCHEMBL11496033 | 0.82 | HSD11B1 (0.45) | HSD11B1POLBTSHRSMN1; SMN2PPID | |
| SCHEMBL313012 | 0.80 | POLB (0.55) | HSD11B1POLBTSHRSMN1; SMN2PPID | |
| SCHEMBL16791428 | 0.76 | PKM (0.58) | SMN1; SMN2ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL6821927 | 0.75 | POLB (0.47) | HSD11B1POLBTSHRSMN1; SMN2PPID | |
| SCHEMBL7127844 | 0.75 | GABRA1 (0.42) | NLRP3TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL19130505 | 0.75 | GABRA1 (0.42) | NLRP3TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL23643713 | 0.74 | CA12 (0.46) | NLRP3HSD11B1POLBTSHRSMN1; SMN2 | |
| SCHEMBL28291723 | 0.74 | LMNA (0.50) | HSD11B1POLBSMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL31294807 | 0.74 | HSD11B1 (0.38) | NLRP3HSD11B1TSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586762-B2 | Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077985-A1 | PROCESS FOR PRODUCING FUSED IMIDAZOLE COMPOUND, REFORMATSKY REAGENT IN STABLE FORM, AND PROCESS FOR PRODUCING THE SAME | CYP17A1, HSD17B7, HSD17B1 | NLRP3 898/4885HSD11B1 7/4885POLB 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.